



FEDERAL BUREAU OF INVESTIGATION SITUATIONAL INFORMATION REPORT

Potential Criminal Activity Alert

Miami Division

01 June 2011

(U//LES) A Popular Prescription Drug Sold in New York May be Establishing a Distribution Network in South Florida, as of June 2011

(U//LES) As of June 2011, a popular prescription drug named “Opana,” sold in New York may become prevalent in South Florida. Two unknown males identifying themselves as “E” (FNU) (LNU) and “L” (FNU) (LNU) are allegedly looking to establish a network to distribute Opana in Miami, Florida. “E” and “L” will be transporting the prescription drug via rental cars from New York to Florida.

Analyst Note: Opana is a prescription drug used to ease severe pain. Its effects are six to eight times more powerful than morphine. Opana has been called the “New Oxycotin.” Opana is also known as Oxymorphone. Oxymorphone or 14-Hydroxydihydromorphone is a powerful semi-synthetic opiod analgesic patented in the United States by Endo Pharmaceuticals. Opana is available in tablets of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg.

(U) This report has been prepared by the Miami Field Division of the FBI. Comments and queries may be addressed to the Miami Field Division Field Intelligence Group at (305) 944-9101.

(U) Law Enforcement Sensitive: This information is the property of the FBI and may be distributed to state, tribal, or local government law enforcement officials with a need-to-know. Further distribution without FBI authorization is prohibited. Precautions should be taken to ensure this information is stored and/or destroyed in a manner that precludes unauthorized access.

(U) Warning: This is an information report, not finally evaluated intelligence. It is being shared for informational purposes but has not been fully evaluated, integrated with other information, interpreted, or analyzed. Receiving agencies are cautioned not to take actions based solely on this raw reporting unless the information is independently verified. A presumption of innocence still exists for any person being reported on in this report.

(U) Note: This product reflects the views of Miami Division and has not been vetted by FBI Headquarters.